Five years ago, NPS Pharmaceuticals Inc. received an FDA "approvable" letter for its osteoporosis candidate Preos (parathyroid hormone), a regulatory action that sent the company into a tailspin of cost cuts and downsizing. Now the Bedminster, NJ-based specialty pharma is gearing up for a second shot at the commercial market. Unlike in 2006, when NPS was focused on therapies for big primary care indications, however, the company believes success will come from a focus on niche gastrointestinal and endocrine disorders.
NPS' tale is as old as the biopharma industry, but rather than pushing ahead with the development of Preos in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?